CO5601024A2 - USE OF ALQUILFOSFOCOLINAS FOR THE PREVENTIVE TREATMENT OF DISEASES CAUSED BY PROTOZOOS - Google Patents
USE OF ALQUILFOSFOCOLINAS FOR THE PREVENTIVE TREATMENT OF DISEASES CAUSED BY PROTOZOOSInfo
- Publication number
- CO5601024A2 CO5601024A2 CO04070642A CO04070642A CO5601024A2 CO 5601024 A2 CO5601024 A2 CO 5601024A2 CO 04070642 A CO04070642 A CO 04070642A CO 04070642 A CO04070642 A CO 04070642A CO 5601024 A2 CO5601024 A2 CO 5601024A2
- Authority
- CO
- Colombia
- Prior art keywords
- preventive treatment
- miltefosine
- active ingredient
- use according
- total daily
- Prior art date
Links
- 230000003449 preventive effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 abstract 4
- 229960003775 miltefosine Drugs 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 abstract 2
- 208000004554 Leishmaniasis Diseases 0.000 abstract 1
- -1 alkyl phosphocholines Chemical class 0.000 abstract 1
- 229950010632 perifosine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1.- El uso de alquilfosfocolinas para la producción de un medicamento para el tratamiento preventivo de enfermedades protozoarias en humanos.2.- El uso de acuerdo con la reivindicación 1, en el cual las dosis diarias totales en el rango de 10 a 250 mg de ingrediente activo de alquilfosfocolina, son administradas oralmente durante un período desde 2 semanas a 6 meses, preferiblemente por la duración del riesgo de infección.3.- El uso de acuerdo con las reivindicaciones 1 y 2, caracterizado en que la hexadecilfosfocolina (miltefosina) u octadecil 1,1-dimetilpiperidinio-4-il fosfato (perifosina), se emplea para la producción de un medicamento para el tratamiento preventivo, en particular de leishmaniasis en humanos mediante la administración oral y Ias dosis diarias totales en el rango de 10 a 250 mg de ingrediente activo de miltefosina o de perifosina, son administradas oralmente durante un período desde 2 semanas a 6 meses, preferiblemente por la duración del riesgo de infección.4.- El uso de acuerdo con las reivindicaciones 1 a 3, caracterizado en que la dosis diaria total es aproximadamente 20 a aproximadamente 150 mg ingrediente activo de miltefosina o perifosina.1.- The use of alkyl phosphocholines for the production of a medicament for the preventive treatment of protozoan diseases in humans. 2.- The use according to claim 1, in which the total daily doses in the range of 10 to 250 mg of active ingredient of alkylphosphocholine, are administered orally for a period from 2 weeks to 6 months, preferably for the duration of the risk of infection.3.- The use according to claims 1 and 2, characterized in that hexadecylphosphocholine (miltefosine) or octadecyl 1,1-dimethylpiperidinium-4-yl phosphate (periposine), is used for the production of a medicament for preventive treatment, in particular leishmaniasis in humans by oral administration and total daily doses in the range of 10 to 250 mg of active ingredient miltefosine or peripheosin, are administered orally for a period from 2 weeks to 6 months, preferably for the duration of the risk of infection. n.4.- The use according to claims 1 to 3, characterized in that the total daily dose is about 20 to about 150 mg active ingredient or perifosine miltefosine.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10203195A DE10203195A1 (en) | 2002-01-25 | 2002-01-25 | Use of alkylphosphocholines in the preventive treatment of protozoal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5601024A2 true CO5601024A2 (en) | 2006-01-31 |
Family
ID=7713213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04070642A CO5601024A2 (en) | 2002-01-25 | 2004-07-23 | USE OF ALQUILFOSFOCOLINAS FOR THE PREVENTIVE TREATMENT OF DISEASES CAUSED BY PROTOZOOS |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1467742A1 (en) |
| JP (1) | JP2005515244A (en) |
| CN (1) | CN1622811A (en) |
| AR (1) | AR038224A1 (en) |
| AU (1) | AU2003236787B2 (en) |
| BR (1) | BR0307021A (en) |
| CA (1) | CA2470185A1 (en) |
| CO (1) | CO5601024A2 (en) |
| DE (1) | DE10203195A1 (en) |
| IL (2) | IL162492A0 (en) |
| MX (1) | MXPA04007193A (en) |
| NZ (1) | NZ548040A (en) |
| PE (1) | PE20030732A1 (en) |
| TW (1) | TWI339582B (en) |
| WO (1) | WO2003061669A1 (en) |
| ZA (1) | ZA200404690B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT501545B1 (en) * | 2005-02-23 | 2007-10-15 | Obwaller Andreas Dr | CLEANING AGENT FOR CONTACT LENSES |
| EP1800684A1 (en) * | 2005-12-20 | 2007-06-27 | Zentaris GmbH | Novel alkyl phospholipid derivatives and uses thereof |
| CA2632449A1 (en) * | 2005-12-19 | 2007-06-28 | Aeterna Zentaris Gmbh | Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| CN104473941A (en) * | 2014-12-20 | 2015-04-01 | 长沙佰顺生物科技有限公司 | Miltefosine-containing medicine preparation and preparation method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4132344A1 (en) * | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | METHOD FOR PRODUCING A MEDAL FOR ORAL OR TOPICAL ADMINISTRATION IN THE TREATMENT OF LEISHMANIASIS |
| DE4132345A1 (en) * | 1991-09-27 | 1993-04-01 | Max Planck Gesellschaft | ETHER LYSOLECITHINES AND ALKYLPHOSPHOCHOLINE IN LIPOSOMES |
| EP0634927B1 (en) * | 1992-03-06 | 2001-07-04 | Lica Pharmaceuticals A/S | Treatment and prophylaxis of diseases caused by parasites, or bacteria |
| EP1051159B1 (en) * | 1998-01-22 | 2002-04-10 | Zentaris AG | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| DE10020812C2 (en) * | 2000-04-20 | 2003-06-26 | Robert Koch Inst | Use of naphthindazole-4,9-quinones as antiparasitic agents |
| AU2002232400A1 (en) * | 2000-11-06 | 2002-05-15 | U.S. Army Medical Research And Materiel Command | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis |
-
2002
- 2002-01-25 DE DE10203195A patent/DE10203195A1/en not_active Withdrawn
-
2003
- 2003-01-07 MX MXPA04007193A patent/MXPA04007193A/en active IP Right Grant
- 2003-01-07 NZ NZ548040A patent/NZ548040A/en not_active IP Right Cessation
- 2003-01-07 WO PCT/EP2003/000072 patent/WO2003061669A1/en not_active Ceased
- 2003-01-07 CN CNA038027062A patent/CN1622811A/en active Pending
- 2003-01-07 BR BR0307021-2A patent/BR0307021A/en not_active Application Discontinuation
- 2003-01-07 JP JP2003561613A patent/JP2005515244A/en active Pending
- 2003-01-07 EP EP03731619A patent/EP1467742A1/en not_active Ceased
- 2003-01-07 CA CA002470185A patent/CA2470185A1/en not_active Abandoned
- 2003-01-07 IL IL16249203A patent/IL162492A0/en unknown
- 2003-01-07 AU AU2003236787A patent/AU2003236787B2/en not_active Expired
- 2003-01-13 TW TW092100614A patent/TWI339582B/en not_active IP Right Cessation
- 2003-01-20 PE PE2003000061A patent/PE20030732A1/en not_active Application Discontinuation
- 2003-01-24 AR ARP030100214A patent/AR038224A1/en unknown
-
2004
- 2004-06-14 ZA ZA200404690A patent/ZA200404690B/en unknown
- 2004-06-14 IL IL162492A patent/IL162492A/en active IP Right Grant
- 2004-07-23 CO CO04070642A patent/CO5601024A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2470185A1 (en) | 2003-07-31 |
| PE20030732A1 (en) | 2003-09-27 |
| DE10203195A1 (en) | 2003-08-07 |
| WO2003061669A1 (en) | 2003-07-31 |
| NZ548040A (en) | 2007-06-29 |
| JP2005515244A (en) | 2005-05-26 |
| AR038224A1 (en) | 2005-01-05 |
| AU2003236787B2 (en) | 2007-03-22 |
| MXPA04007193A (en) | 2004-10-29 |
| IL162492A0 (en) | 2005-11-20 |
| TWI339582B (en) | 2011-04-01 |
| TW200302103A (en) | 2003-08-01 |
| CN1622811A (en) | 2005-06-01 |
| ZA200404690B (en) | 2004-09-27 |
| BR0307021A (en) | 2004-11-03 |
| EP1467742A1 (en) | 2004-10-20 |
| IL162492A (en) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05002883A (en) | Dosage forms and related therapies. | |
| CR9662A (en) | ACTIVE CANABINOID PHARMACEUTICAL INGREDIENT FOR IMPROVED DOSE FORMS | |
| ES2156028T3 (en) | Compositions containing tetrahydrolipstatin | |
| CR8352A (en) | PHARMACEUTICAL FORMULATIONS, PROCEDURES AND DOSAGE GUIDELINES FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES | |
| ES2141706T3 (en) | FORMULATIONS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES. | |
| RU94046316A (en) | Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment | |
| BRPI0413756A (en) | compound, methods for treating or preventing spasticity or a symptom of spasticity, gastro-oesophageal reflux disease, drug addiction, alcohol addiction or abuse, or nicotine abuse or addiction, and cough or emesis in a patient, and, pharmaceutical composition | |
| BR9916224A (en) | Oral pharmaceutical dosage form, processes for the manufacture of a fixed dosage form, for the treatment and prophylaxis of gastrointestinal disorders and to prevent gastrointestinal side effects, use of a dosage form, combination, and ampoule packaging | |
| ATE418324T1 (en) | MUCOADHESIVE FORMULATION CONTAINING XYLOGLUCAN FOR MEDICAL DEVICES AND PHARMACEUTICAL DOSAGE FORMS | |
| AR046773A1 (en) | PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATES | |
| TR200102067T2 (en) | Applicator for delivering topical formulations to the mucous cavity | |
| MXPA02012792A (en) | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates. | |
| MXPA05003366A (en) | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof. | |
| BR0104228A (en) | Alkylamino acid derivatives useful as pharmaceutical agents, method for making a compound, pharmaceutical composition, methods for various treatments and use of a compound in the manufacture of a medicine for various treatments | |
| ES2175663T3 (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MILTEPHOSINE FOR ORAL ADMINISTRATION IN THE TREATMENT OF LESHMANIASIS. | |
| AR044200A1 (en) | COMPOSITION OF FONDAPARINUX SODICO DE HIGH PURITY, A PROCEDURE FOR THE PREPARATION OF THIS COMPOSITION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AS AN ACTIVE PRINCIPLE | |
| AR037560A1 (en) | FORMULATION OF HIGH DOSES OF IBANDRONATO | |
| AR030039A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A SELECTIVE INHIBITOR DRUG OF CYCLOOXYGENASA-2, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT OR PREVENT AFFECTIONS THROUGH CYCLOOXYGENASE-2 AND METHOD TO MAKE SUCH MEDICINAL PRODUCT | |
| AR033151A1 (en) | AGENT FOR THE TOPICAL OPHTHALMIC TREATMENT OF OCULAR INFLAMMATORY DISEASES | |
| HUP0401672A2 (en) | Low concentration of peroxide for treating or preventing vaginal infections | |
| CL2024003616A1 (en) | Oral pharmaceutical composition and use for the therapy of progressive fibrosing interstitial lung diseases. | |
| ES2108014T3 (en) | ANTIVIRAL COMPOSITION OF 3'-AZIDO-2 ', 3'-DIDEOXI-5-METHYLCITIDINE. | |
| CO5601024A2 (en) | USE OF ALQUILFOSFOCOLINAS FOR THE PREVENTIVE TREATMENT OF DISEASES CAUSED BY PROTOZOOS | |
| RU2007104774A (en) | COMBINATION OF ANTI-HIV REVERSE TRANSCRIPTASE AND PROTEASES INHIBITORS | |
| AR013994A1 (en) | PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |